Bearish
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary...
Bearish
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary...
Bullish
DexCom Inc (DXCM) shares rose 3.5% to $71.25 and are currently classified as significantly undervalued according to GuruFocus's GF Value™ of $103.81, ...
Neutral
This article provides financial information for DexCom, Inc. (SIX:DXCM), specifically focusing on its price-to-sales forward ratio. It appears to be a...
DexCom, Inc. (DXCM) announced FDA clearance for expanded use of its Stelo Glucose Biosensor, now including children aged 2 and older who do not use in...
Levi & Korsinsky, LLP has initiated a securities class action lawsuit against DexCom, Inc. (DXCM) on behalf of investors who suffered losses between J...
Neutral
DexCom Inc. (DXCM) stock fell 1.58% to $68.65 on Thursday, underperforming the broader market. This drop occurred during a mixed trading session where...
Bullish
Deutsche Bank has initiated coverage of Insulet (PODD) and DexCom (DXCM) with Buy ratings, leading to gains for the MedTech companies. This positive a...
Bearish
DexCom Inc. (DXCM) shares fell by 2.64% to $71.23 on Wednesday, underperforming the broader stock market. The S&P 500 Index (SPX) also declined by 1.2...
DexCom's EVP and Chief Legal Compliance Officer, Michael Jon Brown, sold 1,700 shares of common stock at $75.55 per share on June 15, 2026. This trans...
Dexcom Inc. director Mark G. Foletta's family trust sold 4,000 common shares of DXCM on June 15, 2026, through open-market transactions under a pre-ar...
Bullish
TD Cowen increased its price target for DexCom Inc. (NASDAQ:DXCM) shares to $95 from $75, maintaining a Buy rating, after new data was presented at th...
Bullish
Mizuho increased its price target for DexCom Inc. (NASDAQ:DXCM) shares to $85 from $75, maintaining an Outperform rating, following positive results f...
Bullish
Mizuho Securities has increased its price target for DexCom (DXCM) to $85 from $75, while reiterating an "Outperform" rating on the stock. This adjust...
Stifel has raised its price target for DexCom (DXCM) to $90 from $85, reiterating a Buy rating on the stock. This adjustment comes amidst recent news ...